Revolutionizing the drug discovery stages with cutting-edge AI-driven Software Solutions.
HubMed© is a Swiss Made AI-powered Platform purpose-built to transform the operational efficiency of the R&D teams in the Nutraceutical, Cosmetics, and Medical Devices sectors.
Talk to Sales
HubMed©Platform
Accelerate research. Trusted insights. Transparent results and better outcomes.
By leveraging advanced AI-driven solutions, HubMed© revolutionizes the drug discovery process, helping R&D teams accelerate each stage and significantly reduce the time to market for new products.
HubMed©, a Platform extensively validated by scientists, is based on 2 Solutions specifically designed to address the preclinical and clinical stages of the R&D Process.
With its comprehensive modular approach and Swiss Made Software quality HubMed© stands as a transformative platform for organizations aiming to innovate faster and bring safe, effective products to market with confidence.
HubMed© supports the entire R&D pipeline, from early discovery and target identification to clinical development, delivering faster, evidence-based decisions at every stage
Thanks to a modular architecture addressing the R&D stages of preclinical and clinical process, research organizations can expect to shorten the time required for discovery phases up to 70%.
Learn how HubMed©Platform is transforming pre-clinical and clinical operations with smart, scalable, and AI-powered solutions.
"This can be a massive time-saver for us. The complete HubMed suite enables us to do a target prioritization exercise in few hours days, that would otherwise take weeks or even months to complete.”
Medea
Preclinical research encompasses the early phases of drug discovery, from target identification to the nomination of a preclinical candidate and extends to later stages that include safety and toxicology studies, process scale-up, and pharmaceutical development. Traditional research methods for identifying and prioritizing biomedical research targets are time-consuming — and most often, not comprehensive.
Medea makes use of advanced AI technology to streamline this process: by analyzing vast amounts of biomedical data and presenting scientists with the most relevant information, saving time and effort.
Medea is composed of specialized modules, each tailored to address a critical phase of the stages in preclinical process:
- Molecule Screening: This module enables rapid and intelligent screening of molecular candidates, helping researchers identify promising compounds early in the process.
- Receptorial Analysis: HubMed provides sophisticated tools for analyzing how candidate molecules interact with biological receptors, supporting more targeted and effective product development.
- Toxicological Analysis: Ensuring safety is paramount. This module streamlines toxicological assessments, allowing teams to evaluate potential risks efficiently and comply with regulatory standards.
A Solution dedicated to the Clinical stages.
ArchiMed, is the platform specifically designed for Contract Research Organizations (CROs) and those Sponsors having a compliance team in-house. ArchiMed helps R&D teams, to automate and accelerate compliance processes, reducing the time required to meet regulatory requirements and further shortening the path to market for innovative products.
Intuitive Experience.
The HubMed©Platform and its two solutions (Medea and ArchiMed), are engineered with user experience at its core. Its intuitive interface ensures that both seasoned researchers and new team members can navigate the platform with ease—no steep learning curve or extensive training required. The streamlined workflows and clear visualizations empower users to focus on scientific innovation rather than software complexity, making HubMed© an ideal solution for organizations seeking rapid onboarding and immediate productivity.
Designed for Efficiency in Drug Discovery.
With two solutions- namely Medea and ArchiMed- and dedicated modules for each stage of the R&D process- i.e. from molecule screening to receptorial analysis and toxicological evaluation, up to regulatory compliance, HubMed© adapts to the unique needs of organizations operating within the Nutraceutical, Cosmetics, and Medical Devices sectors.
R&D teams can use specific modules or leverage the entire suite for an end-to-end solution.
HubMed© is purpose-built to improve efficiency during the most critical early stages of drug discovery. By automating routine tasks, integrating multidisciplinary data, and providing actionable AI-driven insights, HubMed© enables research teams to make faster, more informed decisions. This targeted approach not only accelerates the identification and validation of therapeutic targets but also optimizes the transition from hit selection to preclinical candidate identification.
Dramatic Reduction in Discovery Timelines.
HubMed©’s AI-driven modules streamline every stage of the R&D process, enabling teams to move from molecule screening to toxicological analysis with greater speed and precision. This acceleration helps organizations bring new products to market faster, gaining a competitive edge.
With HubMed©, organizations can expect to shorten the time required for early discovery phases by an impressive 50%—and in some cases, up to 70%.
This substantial reduction is achieved through advanced AI algorithms, seamless data integration and features that eliminate bottlenecks and streamline every step of the process. By accelerating research timelines, HubMed© empowers your company to bring innovative product to market faster, giving you a decisive competitive advantage.
The ArchiMed solution automates and simplifies regulatory compliance, reducing the time and effort required to meet industry standards. This not only accelerates product launches but also minimizes risks associated with non-compliance.
One platform for faster, more reliable decisions.
Life sciences R&D is slowed by siloed teams, manual work, and fragmented tools, leading to long, risky cycles with unclear impact. As a Swiss Made Software, HubMed© continuously pulls data from internal and external sources across the landscape of biomedical knowledge and ensures information is constantly up to date.
The Platform embodies the precision, reliability, and security associated with Swiss engineering. Organizations can trust the platform to deliver robust performance and safeguard sensitive R&D data.